ClinicalTrials.gg
Enrolling by invitationNCT04003311Updated Oct 30, 2025

MDR - Comprehensive Primary/Micro Stem & Versa-Dial Ti Humeral Head

An observational study in Shoulder Pain, Shoulder Injuries and Shoulder Fractures, sponsored by Zimmer Biomet. Enrolling by invitation at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-30.

Sponsored by Zimmer Biomet · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
146
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 146 studies in Shoulder Pain with a site in United States — 21 open to participants now, 28 under way, none of them phase 3. Shoulder Pain · United States.

Planned enrollment
5th of 24
146 · median 65
Started
2019
with 14 others
Observational
24 of 146
6 open now
Primary completion
2028-07
later than 22 of 27 live
Registered
92nd of 146
by date
Lead sponsor
6 of 146
Zimmer Biomet

Among the 146 studies in Shoulder Pain with a site in United States, this one is the 5th largest by planned enrollment of the 24 observational ones that give a count, is one of 15 that started in 2019, is one of 24 observational ones, reaches primary completion later than 22 of the 27 other live ones, and was the 92nd registered.

Shoulder Pain

738 studies on the registry are indexed under Shoulder Pain; 168 are open to participants now.

Browse Shoulder Pain studies →

Open to participants now

21 of the 146 studies in Shoulder Pain with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 90 Shoulder Pain studies recruiting now, 25 (28%) set no upper age limit and 55 (61%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies in Shoulder Pain with a site in United States, or all of them as a file.
02

Study summary

The objective of this retrospective/prospective enrollment and prospective follow-up consecutive series PMCF study is to collect data confirming safety, performance and clinical benefits of the Comprehensive Primary Micro Stem and Comprehensive Anatomic Versa-Dial Titanium Humeral Heads when used for primary and revision total shoulder arthroplasty (implants and instrumentation) at 1,3,5,7 and 10 years*. Comprehensive Primary Micro Stem and Comprehensive Anatomic Versa-Dial Titanium Humeral Heads have been on the market since 2007, but have insufficient data to support 10 years of clinical history. Therefore, a prospective aspect to the study will be utilized in order to collect long-term data.

Read the detailed description

The objective of this retrospective/prospective enrollment and prospective follow-up consecutive series PMCF study is to collect data confirming safety, performance and clinical benefits of the Comprehensive Primary Micro Stem and Comprehensive Anatomic Versa-Dial Titanium Humeral Heads when used for primary and revision total shoulder arthroplasty (implants and instrumentation) at 1,2,3,5,7 and 10 years*. Comprehensive Primary Micro Stem and Comprehensive Anatomic Versa-Dial Titanium Humeral Heads have been on the market since 2007, but have insufficient data to support 10 years of clinical history. Therefore, a prospective aspect to the study will be utilized in order to collect long-term data.

The primary objective of this study is the assessment of safety by analyzing implant survivorship. This will be established by recording the incidence and frequency of revisions, complications, and adverse events. Relation of the events to either implant or instrumentation should be specified.

The secondary objective is the assessment of performance and clinical benefits by recording patient-reported clinical outcomes measures (PROMs).

*The most recent available data will be used. If any of the listed time points are not available, data will be used from last available time point and follow-up will move forward at the closest available time point.

03

Conditions studied

  • Shoulder Pain
  • Shoulder Injuries
  • Shoulder Fractures
  • Shoulder Disease
  • Shoulder Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

A consecutive series of subjects implanted with the Comprehensive Primary Micro Stem and/or the Comprehensive Anatomic Versa-Dial Titanium Humeral Heads in primary and/or revision total shoulder arthroplasty according to the approved indications.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study devices must have been implanted following the surgical technique and IFU for the Comprehensive Micro Stem and/or the Comprehensive Anatomic Versa-Dial Humeral Heads
  • Patient must be 18 years of age or older.
  • Patient must have undergone a primary or revision shoulder arthroplasty with the Comprehensive Micro Stem and/or the Comprehensive Anatomic Versa-Dial Humeral Heads for a cleared indication. Cleared indications include the following:

    • non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis,
    • rheumatoid arthritis,
    • revision where other devices or treatments have failed,
    • correction of functional deformity,
    • fractures of the proximal humerus where other methods of treatment are deemed inadequate,
    • difficult clinical management problems including cuff arthroplasty where other treatment methods may not be suitable or may be inadequate.

Exclusion criteria

Exclusion Criteria:

  • Absolute include infection, sepsis, and osteomyelitis.
  • Relative contraindications include:

    • Uncooperative patient or patient with neurologic disorders who is incapable or unwilling to follow directions
    • Osteoporosis
    • Metabolic disorders which may impair bone formation
    • Osteomalacia
    • Distant foci of infections which may spread to the implant site
    • Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram
  • Patient is a prisoner.
  • Patient is a current alcohol or drug abuser.
  • Patient is known to be pregnant or breastfeeding.
  • Patient has a psychiatric illness or cognitive deficit that will not allow for proper .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
146 participants (estimated)
Patient registry
No

Groups and cohorts

  • Comprehensive Primary Micro Stem

    Patients that have been implanted with the Comprehensive Primary Micro Stem to repair shoulder malfunction/disease.

    Device: Comprehensive Primary Micro Stem

  • Comprehensive Anatomic Versa-Dial Titanium Humeral Heads

    Patients that have been implanted with the Comprehensive Anatomic Versa-Dial Titanium Humeral Heads to repair shoulder malfunction/disease.

    Device: Comprehensive Anatomic Versa-Dial Titanium Humeral Head

Interventions

  • DeviceComprehensive Primary Micro Stem

    Patients that have been implanted with the Comprehensive Primary Micro Stem to repair shoulder malfunction/disease.

  • DeviceComprehensive Anatomic Versa-Dial Titanium Humeral Head

    Patients that have been implanted with the Comprehensive Anatomic Versa-Dial Titanium Humeral head to repair shoulder malfunction/disease.

06

What researchers measure

Primary outcomes

  1. Device Safety assessed through the frequency and incidence of revisions, complications and Adverse Events

    The primary objective of this study is the assessment of safety by analyzing implant survivorship. This will be established by recording the incidence and frequency of revisions, complications, and adverse events. Relation of the events to either implant or instrumentation should be specified.

    Time frame: Out to 10 years

Secondary outcomes

  1. Device Performance and Benefits evaluated through the Oxford Shoulder Score outcome measure.

    The secondary objective is the assessment of performance and clinical benefits by recording patient-reported clinical outcomes measures (PROMs), through the use of the Oxford Shoulder Score (OSS). The OSS is a 12 item questionnaire, each with 5 potential answers. Patients rate their symptoms from 1 (minimal symptoms) to 5 (severe symptoms). The combined total gives a minimum score of 12 and a maximum of 60. Higher scores in the OSS imply worse functionality.

    Time frame: Out to 10 years

  2. Device Performance and Benefits evaluated through the Patient Assessment Questionnaire.

    The secondary objective is the assessment of performance and clinical benefits by recording patient-reported clinical outcomes measures (PROMs), through the use of the Patient Assessment Questionnaire where adverse events and/or complications (yes or no), patient's activity level with regard to operative side, based on the UCLA Activity Score(wholly inactive 10, mostly inactive 9, sometimes participates in mild activities 8, regularly participates in mild activities 7, sometimes participates in moderate activities 6, regularly participates in moderate activities 5, regularly participates in active events 4, regularly participates in very active events 3, sometimes participates in impact sports 2, regularly participates in impact sports 1, or not recorded), and the Reported Score if Individual Scores are not available of the Oxford Shoulder Score. The UCLA Activity score rating is from 10 being the best outcome score, and 1 being the worst.

    Time frame: Out to 10 years

07

Study locations

4 sites
  • Shoulder Clinic of Idaho
    Boise, Idaho 83704, United States
  • Beaumont Health
    Royal Oak, Michigan 48073, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • Department of Orthopaedics & Rehabilitation The Larner College of Medicine at The University of Vermont
    Burlington, Vermont 05405, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2019 (actual). Primary completion is estimated for Jul 2028, 103 months after the start.

Of 54 observational studies under Shoulder Pain, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 35. This study's planned 103 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2019
First posted
Jul 1, 2019
StartActual
Dec 13, 2019
Primary completionEst.
Jul 29, 2028
CompletionEst.
Jul 29, 2028
Last update
Oct 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04003311
Lead sponsor
Zimmer Biomet
Responsible party
Sponsor
First posted
Jul 1, 2019
Start date
Dec 13, 2019
Primary completion
Jul 29, 2028 (estimated)
Completion
Jul 29, 2028 (estimated)
Last update
Oct 30, 2025

Study contacts

Erin Osborn
study director · Zimmer Biomet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion